实验性肺动脉高血压对接受抵抗运动训练的老鼠脏和骨参数的影响
Leôncio L Soares1, Luciano B Leite1, Maíra O Freitas1
1Federal University of Viçosa, Department of Physical Education, Av. PH Rolfs, s/n, University Campus, Center, 36570-900 Viçosa, MG, Brazil.
Anais da Academia Brasileira de Ciencias
|April 24, 2024
概括
肺动脉高血压 (PAH) 会导致脏损伤,但抵抗运动训练 (RT) 可以预防这些功能障碍. RT还改善了老鼠的骨特性,即使有PAH.
科学领域:
- 心血管生理学心血管生理学
- 脏生理学 脏生理学
- 骨生物学 骨生物学 骨生物学
背景情况:
- 肺动脉高血压 (PAH) 导致右心室衰竭,心脏输出减少,以及潜在的和骨问题.
- 众所周知,抵抗运动训练 (RT) 有助于心血管和骨健康.
研究的目的:
- 为了研究单克罗他林 (MCT) 诱导的PAH和RT对雄性Wistar大鼠的和骨形态学和生物力学的影响.
- 为了确定RT是否可以减轻PAH引起的和骨功能障碍.
主要方法:
- 鼠被分为四组:未经训练的对照,训练的对照,未经训练的高血压 (PAH) 和训练的高血压 (PAH).
- 训练有素的老鼠接受了RT计划 (爬梯) 每周5次.
- 在MCT或盐水注射后,评估了脏和股骨组织形态测量和股骨生物力学特性.
主要成果:
- PAH显著降低了脏球球面积和体积,这种效应被RT阻止.
- PAH没有对股骨形态或生物机械性质产生负面影响.
- RT增强的股骨参数,包括长度,椎百分比,骨髓和承载能力.
结论:
- 在实验中,PAH诱导脏损伤,但不会导致大鼠的骨损伤.
- RT有效地预防PAH引起的脏恶化.
- RT可以改善骨的形态和生物力学特性,而不依赖于PAH的存在.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
159
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159


